QIAGEN NV
QGENF
QGENF was delisted on the 14th of February, 2005.
172 hedge funds and large institutions have $2.89B invested in QIAGEN NV in 2014 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 62 increasing their positions, 59 reducing their positions, and 18 closing their positions.
109% more call options, than puts
Call options by funds: $3.94M | Put options by funds: $1.89M
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
5% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 59
0% more capital invested
Capital invested by funds: $2.88B → $2.89B (+$8.07M)
0% more funds holding
Funds holding: 172 → 172 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$43.5M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$13.9M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$8.77M |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$8.35M |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$8.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$38.7M |
| 2 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
-$38.4M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$23.4M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$17M |
| 5 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$12.3M |
QGENF Hedge Fund Activity: Q4 2014 in Review
172 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in QIAGEN NV (QGENF) for Q4 2014, worth a combined $2.89B — up 0.28% from $2.88B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new QGENF positions and 18 closed out — a net gain of 2 holders — while 62 added to existing stakes and 59 trimmed.
The largest buyer was Franklin Resources, adding an estimated $43.5M. The largest seller was OrbiMed, exiting entirely with an estimated $38.7M sold.
- 172 institutional investors held QIAGEN NV (QGENF) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $2.89B of QIAGEN NV stock for Q4 2014, up 0.28% quarter-over-quarter.
- 20 funds opened new QIAGEN NV positions in Q4 2014 and 18 closed out, a net change of +2 holders.
- The largest QIAGEN NV buyer in Q4 2014 was Franklin Resources, an estimated $43.5M added.
- The largest QIAGEN NV seller in Q4 2014 was OrbiMed, an estimated $38.7M sold.
Based on aggregated 13F filings for Q4 2014.